Kras/nras/braf mutations as potential targets in multiple myeloma

Sergiu Pasca, Ciprian Tomuleasa, Patric Teodorescu, Gabriel Ghiaur, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, Aaron Ciechanover, Herman Einsele

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


In multiple myeloma the mutational profile is mainly represented by translocations involving chromosome 14 and by single nucleotide mutations, frequently involving genes implicated in the mitogen activated protein kinase (MAPK) pathway, as KRAS, NRAS, and, less frequently, BRAF. Because KRAS/NRAS/BRAF mutations are associated with a higher number of mutations per patient, we hypothesize that this group of patients could benefit from therapy with checkpoint inhibitors because of the higher frequency of neo-antigens that this group would present. This might also true for IMiD therapy, because of their activatory effect on T cells. Because, KRAS/NRAS/BRAF are members of the MAPK pathway, this subgroup of patients would also benefit from inhibitors of MAPK, either directly on the specific mutation or through downstream targeting of MEK1/2 or ERK1/2 to account for a possible compensatory collateral signaling that might activate as response to upstream inhibition.

Original languageEnglish (US)
Article number1137
JournalFrontiers in Oncology
Issue numberOCT
StatePublished - 2019


  • BRAF
  • KRAS
  • Multiple myeloma
  • NRAS
  • Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Kras/nras/braf mutations as potential targets in multiple myeloma'. Together they form a unique fingerprint.

Cite this